Cargando…

Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease

Gut microbial dysbiosis and altered metabonomics have been implicated in the pathogenesis of Crohn’s disease (CD). The aim of our study was to characterize the gut microbiome structure and metabolic activities in pediatric CD patients with different clinical outcomes after infliximab (IFX) therapy....

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yizhong, Gao, Xuefeng, Zhang, Xinyue, Xiao, Fangfei, Hu, Hui, Li, Xiaolu, Dong, Fang, Sun, Mingming, Xiao, Yongmei, Ge, Ting, Li, Dan, Yu, Guangjun, Liu, Zhanju, Zhang, Ting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808429/ https://www.ncbi.nlm.nih.gov/pubmed/33430702 http://dx.doi.org/10.1080/19490976.2020.1865708

Ejemplares similares

Henoch-Schönlein purpura associated with infliximab therapy for pediatric Crohn’s disease
por: Li, Xiaolu, et al.
Publicado: (2022)

Bifidobacterium longum CECT 7894 Improves the Efficacy of Infliximab for DSS-Induced Colitis via Regulating the Gut Microbiota and Bile Acid Metabolism
por: Xiao, Fangfei, et al.
Publicado: (2022)

Altered gut microbiota and microbial metabolism in children with hepatic glycogen storage disease: a case-control study
por: Wang, Yizhong, et al.
Publicado: (2023)

Characteristics and management of children with Clostridioides difficile infection at a tertiary pediatric hospital in China
por: Li, Xiaolu, et al.
Publicado: (2022)

Case Report: Pediatric Recurrent Acute Liver Failure Caused by Neuroblastoma Amplified Sequence (NBAS) Gene Mutations
por: Jiang, Bingxin, et al.
Publicado: (2021)

Clinical Efficacy and Microbiome Changes Following Fecal Microbiota Transplantation in Children With Recurrent Clostridium Difficile Infection
por: Li, Xiaolu, et al.
Publicado: (2018)

Gut Microbiota Dysbiosis Is Associated with Altered Bile Acid Metabolism in Infantile Cholestasis
por: Wang, Yizhong, et al.
Publicado: (2019)

Clinical and molecular features of children with Beckwith-Wiedemann syndrome in China: a single-center retrospective cohort study
por: Wang, Ruixue, et al.
Publicado: (2020)

Pediococcus pentosaceus CECT 8330 protects DSS-induced colitis and regulates the intestinal microbiota and immune responses in mice
por: Dong, Fang, et al.
Publicado: (2022)

One case of arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome featuring an incomplete and mild phenotype
por: Yu, Lianhu, et al.
Publicado: (2022)

Probiotics for prevention and treatment of respiratory tract infections in children: A systematic review and meta-analysis of randomized controlled trials
por: Wang, Yizhong, et al.
Publicado: (2016)

Novel compound heterozygote mutations of TJP2 in a Chinese child with progressive cholestatic liver disease
por: Ge, Ting, et al.
Publicado: (2019)

Case Report: A Novel Compound Heterozygous Mutation in IL-10RA in a Chinese Child With Very Early-Onset Inflammatory Bowel Disease
por: Dong, Fang, et al.
Publicado: (2021)

Prevalence of malnutrition and risk of undernutrition in hospitalised children with liver disease
por: Yu, Ronghua, et al.
Publicado: (2017)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Infliximab therapy in pediatric Crohn’s disease: a review
por: Parashette, Kalyan Ray, et al.
Publicado: (2010)

F. prausnitzii-derived extracellular vesicles attenuate experimental colitis by regulating intestinal homeostasis in mice
por: Ye, Lin, et al.
Publicado: (2023)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

Fecal Microbiota Transplantation is a Promising Switch Therapy for Patients with Prior Failure of Infliximab in Crohn’s Disease
por: Li, Qianqian, et al.
Publicado: (2021)

Musculoskeletal actinomycosis in children: a case report
por: Mou, Yani, et al.
Publicado: (2021)

Atypical Late-Onset Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome with Intractable Diarrhea: A Case Report
por: Ge, Ting, et al.
Publicado: (2017)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn's Disease
por: Luo, Youyou, et al.
Publicado: (2017)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn's Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa
por: Yu, Lijuan, et al.
Publicado: (2015)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
por: Choi, So Yoon, et al.
Publicado: (2023)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

Infliximab Combined with Enteral Nutrition for Managing Crohn's Disease Complicated with Intestinal Fistulas
por: Wu, Xiao-Li, et al.
Publicado: (2016)

Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy
por: Cao, Wan-Ting, et al.
Publicado: (2022)

Evaluating the effectiveness of infliximab on perianal fistulizing Crohn’s disease by magnetic resonance imaging
por: Yan, Xiaohan, et al.
Publicado: (2019)

Metastatic Crohn’s disease despite infliximab therapy
por: Campos, Sara, et al.
Publicado: (2017)

Myelolipoma After Infliximab Treatment for Crohn's Disease
por: Cesa, Kevin, et al.
Publicado: (2022)

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn’s disease
por: Ma, Ye, et al.
Publicado: (2023)

Infliximab‐induced seizures in a patient with Crohn’s disease: a case report
por: Lv, Zhijie, et al.
Publicado: (2021)

Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up
por: Lee, Yun Seok, et al.
Publicado: (2012)

Short-Term Outcome of Infliximab Therapy in Pediatric Crohn's Disease: A Single-Center Experience
por: Jung, Dai, et al.
Publicado: (2017)

Infliximab Therapy Could Decrease the Risk of the Development of Thyroid Disorders in Pediatric Patients With Crohn's Disease
por: Furtak, Aleksandra, et al.
Publicado: (2020)

The Association Between Genetic Variants, Pharmacokinetics, and Infliximab Efficacy in Pediatric Patients With Crohn's Disease in China
por: Hu, Wenhui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a2dh8el8e3rq0q5eogiu75jskn